Myelofibrosis (MF) ana kiransa myelofibrosis. Haka kuma cuta ce da ba kasafai ba. Kuma ba a san dalilin da ya haifar da cutar ba. Bayyanar cututtuka na al'ada sune ƙananan ƙwayoyin jini na jini da ƙananan granulocytic anemia tare da adadi mai yawa na zubar da jajayen jini. Burin kasusuwan kasusuwa yakan nuna busasshen busasshen busassun busassun busassun busassun busassun busassun busassun busassun busassun busassun busassun busassun busassun busassun busassun busassun busassun busassun busassun busassun busassun busassun busassun busassun busassun busassun busassun busassun busassun busassun busassun busassun), kuma galibin saifa yana kara girma da mabanbantan matakan osteosclerosis.
Myelofibrosis na farko (PMF) cuta ce ta clonal myeloproliferative cuta (MPD) na ƙwayoyin sel hematopoietic. Maganin myelofibrosis na farko yana da tallafi da farko, gami da ƙarin jini. Ana iya ba da hydroxyurea don thrombocytosis. Ƙananan haɗari, marasa lafiya asymptomatic za a iya lura ba tare da magani ba.
An yi nazarin karatun kashi na uku na bazuwar (STUDY1 da 2) a cikin marasa lafiya tare da MF (MF na farko, post-geniculocytosis MF, ko post-primary thrombocythemia MF). A cikin duka karatun biyu, marasa lafiya da suka yi rajista suna da splenomegaly aƙalla 5 cm a ƙasa da haƙarƙarin haƙarƙarin kuma sun kasance a matsakaici (2 abubuwan haɓakawa) ko babban haɗari (3 ko ƙarin abubuwan haɓakawa) bisa ga ka'idodin yarjejeniya na Ƙungiyar Aiki ta Duniya (IWG).
Kashi na farko na ruxolitinib ya dogara ne akan ƙididdigar platelet. 15 MG sau biyu kowace rana ga marasa lafiya tare da ƙididdigar platelet tsakanin 100 da 200 x 10^9/L da 20 MG sau biyu kowace rana ga marasa lafiya da platelet ƙidaya sama da 200 x 10^9/L.
An ba da allurai guda ɗaya bisa ga haƙuri da inganci ga marasa lafiya tare da ƙididdigar platelet tsakanin 100 da 125 x 10 ^ 9 / L, tare da matsakaicin adadin 20 MG sau biyu a rana; ga marasa lafiya da platelet ƙidaya tsakanin 75 da 100 x 10^9/L, 10 MG sau biyu a rana; kuma ga marasa lafiya da platelet ƙidaya tsakanin 50 zuwa ƙasa da ko daidai da 75 x 10^9/L, sau 2 kowace rana a 5mg kowane lokaci.
Ruxolitinibshi ne na baka JAK1 da JAK2 tyrosine kinase inhibitor da aka amince da shi a cikin Tarayyar Turai a watan Agusta 2012 don maganin matsakaici ko babban haɗari na myelofibrosis, ciki har da myelofibrosis na farko, post-geniculocytosis myelofibrosis da post-primary thrombocythemia myelofibrosis. A halin yanzu, an amince da ruxolitinib Jakavi a cikin fiye da ƙasashe 50 na duniya, ciki har da Tarayyar Turai, Kanada da wasu ƙasashen Asiya, Latin da Kudancin Amirka.